Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 15 days · First seen about 1 month ago · Last updated 19 days ago

Huons pharmaceutical and biotechnology developments

Overview

Huons Lab, a subsidiary of Huons Global, has secured intellectual property rights for its HyDIFFUZE platform technology. The company completed domestic patent registrations and international patent applications for 11 different antibody drug subcutaneous compositions. This technology uses recombinant human hyaluronidase to improve drug dispersion and absorption in subcutaneous tissue.

Following these developments, Huons was selected for three national drug development projects under a South Korean government initiative. Through these projects, Huons will collaborate with various bio-ventures to accelerate clinical entry for several candidates, including an mRNA-lipid nanoparticle eye drop, an antibody-drug conjugate, and a subcutaneous peptide anticancer agent.

Entities

Huons · Pulse In Myer · Pinobio · HyDIFFUZE · Surginex

Timeline

19 days ago

[BUSINESS] 3 sources
Huons selected for three national drug development projects
Huons has secured three national government projects to co-develop new drug pipelines with bio-ventures Surginex, Pinobio, and Pulse In Myer, focusing on mRNA eye drops, ADCs, and peptide anticancer agents.
about 1 month ago

[BUSINESS] 3 sources
Huons Lab secures patents for HyDIFFUZE antibody subcutaneous compositions
Huons Lab has registered domestic patents and filed PCT applications for 11 antibody drug subcutaneous compositions using its HyDIFFUZE platform, which improves drug exposure and concentration.

Sources

biz.heraldcorp.com · bosa.co.kr · hin.company · kormedi.com